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Receptor agonistHepatocyte growth factor (HGF), through activation of the c-MET receptor, mediates biological pro-
cesses critical for tissue regeneration; however, its clinical application is limited by protein instabil-
ity and poor recombinant expression. We previously engineered an HGF fragment (eNK1) that
possesses increased stability and expression yield and developed a c-MET agonist by coupling
eNK1 through an introduced cysteine residue. Here, we further characterize this eNK1 dimer and
show it elicits signiﬁcantly greater c-MET activation, cell migration, and proliferation than the
eNK1 monomer. The efﬁcacy of the eNK1 dimer was similar to HGF, suggesting its promise as a c-
MET agonist.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The c-MET receptor tyrosine kinase has been implicated in the
processes of organogenesis and wound healing, and is dysregulated
in numerous cancermalignancies [1–3]. Given its overexpression in
both developing tissue and tumors, much effort has gone into
developing agonists and antagonists of c-MET for diseases such as
ischemia and cancer, respectively [3–15]. In the case of c-MET ago-
nists, there is a need for molecules that effectively stimulate the
canonical c-MET pathway leading to proliferation, migration, and
survival. Hepatocyte growth factor (HGF) is an 80kDa, multi-
domain protein that is the cognate ligand and activator of c-MET
[1,16]. Despite its biological potency, the clinical adoption of HGF
as a therapeutic for tissue regeneration has been limited by its
inherent instability. Moreover, there are signiﬁcant challenges in
manufacturing such a complex growth factor. HGF can only be pro-
duced in insect or mammalian cells in low quantities; one study
reported a yield of 1.2 mg/L fromChinese hamster ovary cell culture
[17]. Thus, there is great interest in approaches such as gene deliv-
ery for production of HGF [6,18], development of HGF activators
[4,15], or development of alternative c-MET agonists [5,19–22].Many efforts to develop c-MET agonists have focused on a frag-
ment of HGF, termed NK1, which encompasses the N-terminal
domain, a linker region, and the ﬁrst Kringle domain of HGF. The
NK1 fragment contains high-afﬁnity c-MET and heparin binding
sites necessary for functional activity [11,21,23–27]; however, it
is a weak c-MET agonist compared to full-length HGF [23]. NK1
can be recombinantly produced in both bacteria and yeast
[26,28], but like HGF suffers from poor stability and low expression
yields. Previously, we used combinatorial protein engineering to
identify NK1 variants with improved thermostability and up to a
40-fold increase in recombinant expression yield compared to
wild-type NK1 [29]. These NK1 variants functioned as weak ago-
nists or antagonists, depending on retention or mutation of
Asn127 in the linker region, which mediates NK1 homodimeriza-
tion [11,26,29,30]. In addition, we created a covalent dimer by
introducing an N-terminal cysteine residue into an engineered
NK1 agonist (eNK1), which allowed speciﬁc crosslinking through
a disulﬁde bond [29]. This eNK1 dimer functioned as a c-MET ago-
nist, as measured through cell scatter and expression of urokinase-
type plasminogen activator.
Here, we show that the covalent eNK1 dimer can act as a surro-
gate for HGF by testing its ability to stimulate c-MET activation,
cell migration, and cell proliferation compared to HGF and the
eNK1 monomer. The eNK1 dimer offers the combined properties
of high thermostability, ease of recombinant production in yeast,
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further therapeutic development.
2. Materials and methods
2.1. Cells and reagents
The term ‘‘eNK1 monomer’’ refers to the engineered NK1 vari-
ant M2.2 D127N, and ‘‘eNK1 dimer’’ refers to the disulﬁde-linked
dimer cd D127N from our previous work [29]. HGF was from
R&D Systems. FGFb was from GIBCO. BaF3-MET cells were pro-
vided by Patrick Ma, Case Western Reserve University. BaF3-MET
growth media was RPMI 1640 mediumwith Glutamax (Invitrogen)
with 10% fetal bovine serum (FBS) (American Type Culture Collec-
tion), 1% penicillin–streptomycin, 0.5 ng/ml mouse interleukin-3
(R&D Systems), and 1 mg/ml Geneticin (GIBCO). Human umbilical
vein endothelial cells (HUVECs) and the EGM-2 BulletKit were pur-
chased from Lonza Walkersville Inc. A549 cells were grown in Dul-
becco’s Modiﬁed Eagle Media (Invitrogen) with 10% FBS and 1%
penicillin–streptomycin. The PE-conjugated anti-FLAG antibody
for binding assays was from Prozyme. Primary antibodies for Wes-
tern blot analysis were all from Cell Signaling except for b-tubulin
(Covance) and c-MET (Santa Cruz Biotechnology). All secondary
antibodies were purchased from Jackson ImmunoResearch, and
chemiluminescent substrate was from ThermoScientiﬁc. NP-40
buffer was composed of 20 mM Tris pH 8.0, 137 mM NaCl, 10%
glycerol, and 1% IGEPAL/NP40. All cells and reagents for the Path-
Hunter Assay were from DiscoveRx Corporation.
2.2. Yeast production of NK1 variants
Growth and induction media for recombinant protein
expression in Pichia pastoris and detailed protein puriﬁcation
methods were as previously described [29]. The eNK1 dimer was
produced by expression of a modiﬁed variant of eNK1 containingFig. 1. Biochemical and biophysical characterization of eNK1 monomer and dimer,
Representative competition binding curves of eNK1 monomer and dimer on HUVECs, me
of eNK1 monomer and dimer acquired at 20 C. (D) Thermal melting curves of eNK1 mo
indicated by ﬁlled circles, and eNK1 dimer by open circles.an N-terminal cysteine residue. Protein purity was analyzed using
SDS–PAGE and quantiﬁed using a Nanodrop 2000 (Thermo
Scientiﬁc) with the extinction coefﬁcients 25662 M1 cm1 for
the eNK1 monomer and 51324 M1 cm1 for the eNK1 dimer. Pro-
tein was ﬂash-frozen in 0.1% Tween-20 in 1 phosphate buffered
saline containing an additional 500 mM NaCl (PBS500) and stored
at -80 C. Thawed protein was kept at 4 C and used within three
weeks. In Fig. 1A, puriﬁed proteins were analyzed on a 4–12%
Bis-Tris gel (Invitrogen).
2.3. Circular dichroism
Circular dichroism (CD) spectroscopy was performed using a
J-815 CD Spectropolarimeter (Jasco Corporation). eNK1 monomer
and eNK1 dimer were diluted in 1 PBS and spectra were collected
at 20 C from k = 180–260 nm. Thermal melts were performed over
a temperature range of 30–90 C. The Tm,eff was ﬁt to a two-
state unfolding curve using GraphPad Prism 6. Values in Table 1
represent the standard deviation of triplicate experiments.
2.4. Cell binding assays
For competition binding assays, a monomeric NK1 variant con-
taining a FLAG epitope tag (FLAG-M2.2 D127A) [29] was used as a
competitor. Competitor concentrations of FLAG-M2.2 D127A were
12 nM and 15 nM for HUVECs and BaF3-MET, respectively. HUVECs
were incubated with 600 ng/ml of FGFb for 2 h at 4 C to block hep-
aran sulfate on the cell surface [29], followed by washing with
BPBS (1 PBS + 0.1% bovine serum albumin (BSA)). After incuba-
tion with NK1 variants and competitor for 5 h, cells were washed
with BPBS and incubated with PE-conjugated anti-FLAG antibody
for 20 min at 4 C, then washed and analyzed by ﬂow cytometry
using a Guava EasyCyte (Millipore). All data was analyzed using
Flow-Jo software and IC50 values were determined by ﬁtting to a
four-parameter sigmoidal curve using GraphPad Prism 6. Binding(A) Non-reduced SDS–PAGE of puriﬁed eNK1 monomer and eNK1 dimer. (B)
asured by ﬂow cytometry and normalized to maximal binding levels. (C) CD spectra
nomer and dimer as measured by CD spectroscopy. In all panels, eNK1 monomer is
Table 1
Melting temperature (Tm,eff) and relative binding afﬁnty (IC50) for two cell types.
Tm,eff (C) IC50 (nM)
HUVEC BaF3-MET
eNK1 65.0 ± 0.2 1.8 ± 0.7 2.2 ± 0.4
eNK1 dimer 61.9 ± 0.7 0.023 ± 0.019 0.014 ± 0.004
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tion. Values in Table 1 represent the standard deviation of tripli-
cate experiments.
2.5. Phosphorylation assays
HUVECs or A549 cells were grown until 50% conﬂuence. Cell
quiescence was induced by incubation for 12 h in basal
media + 0.1% BSA, followed by addition of either 1 nM or 10 pM
HGF or NK1 variants. Cells were incubated for the indicated times
at 37 C/5% CO2, then lysed with NP-40 buffer containing protease
and phosphatase inhibitors (Thermo Scientiﬁc). Equal amounts of
lysate were loaded on Tris–Glycine gels (Invitrogen) and trans-
ferred onto nitrocellulose membranes. Western Blot analysis was
performed with the reagents listed above. Chemiluminescence
was detected using the ChemiDoc XRS System (Bio-Rad).
2.6. DiscoveRx PathHunter platform
This assay, which was performed according to the manufac-
turer’s instructions, uses enzyme fragment complementation tech-
nology, where c-MET dimerization and trans-phosphorylation
induces a downstream reaction with chemiluminescence as the
output. Relative chemiluminescence therefore corresponds to the
level of c-MET phosphorylation and activation. Brieﬂy, PathHun-
ter proprietary U2OS cells were seeded in CP16 media and grown
overnight at 37 C. HGF or NK1 variants were added to the cells and
incubated for 3 h at room temperature. PathHunter Detection
Reagent was added to each well, and incubated for 1 h at room
temperature in the dark. Chemiluminescence was measured using
a microtiter plate reader (BioTek).
2.7. Cell migration assay
1.3  104 HUVECs were plated and grown to conﬂuency. After
inducing quiescence by incubating for 12 h in basal media + 0.1%
BSA, a horizontal ‘‘wound’’ was created in cell monolayers using
a scratching device. HGF or NK1 variants were added to the wells,
along with 10 pM FGFb, and plates were incubated at 37 C/5% CO2.
Images were taken at 0 and 24 h using an ImageXpress 5000A
Scanner (Molecular Devices). Controls of HGF or NK1 variants
without FGFb, FGFb alone (negative control) or HUVEC complete
growth media (positive control) were included in each assay. Ima-
geJ was used to measure the wound area at both time points, and
the average fraction wound closure was calculated for each condi-
tion over triplicate samples. The experiment was performed three
times.
2.8. Cell proliferation assay
4  103 HUVECs were seeded and grown for 24 h, and quies-
cence was induced by incubating for 12 h in basal media + 0.1%
BSA. HGF or NK1 variants were then added, along with 10 pM
FGFb, and incubated for 24 h at 37 C/5% CO2. Next, 2 lCi tritiated
thymidine (MP Biomedicals) was added to each well and incubated
for an additional 24 h at 37 C/5% CO2, after which the supernatantwas removed and the cells lysed via freeze–thaw. The amount of
tritiated thymidine incorporated into newly synthesized DNA
was measured using a scintillation counter (PerkinElmer). Error
bars represent the standard deviation of triplicate wells. Data
was measured against negative control with only FGFb added.
3. Results
3.1. eNK1 dimer retains biophysical characteristics of the eNK1
monomer, while exhibiting increased c-MET binding afﬁnity
The eNK1 monomer and disulﬁde-linked eNK1 dimer were sol-
ubly expressed in P. pastoris, followed by puriﬁcation using metal
chelating chromatography and size exclusion chromatography.
Protein purity was assessed by SDS–PAGE (Fig. 1A). Competition
binding assays were used to determine the apparent afﬁnities of
eNK1 monomer or eNK1 dimer to c-MET expressed on the surface
of BaF3-MET, a murine cell line transfected with human c-MET
receptor, [31] and HUVECs, a primary cell line used extensively
in angiogenesis and tissue regeneration studies [32–34]. eNK1
retains strong binding to heparin/heparan sulfate proteoglycans
(HSPG) [29]. Thus, direct measurement of eNK1/c-MET interactions
was facilitated by BaF3-MET cells, which lack heparin/HSPG on
their surface [35]. Since HUVECs express heparan sulfate, cells
were preincubated with basic ﬁbroblast growth factor (FGFb) prior
to binding assays, as we previously showed this strategy could
effectively block heparin binding sites [29]. For both cell lines,
the eNK1 dimer had a signiﬁcantly lower half-maximal inhibitory
concentration value (IC50) in the picomolar range compared to
the eNK1 monomer, indicating that dimerization increases the
apparent binding afﬁnity by over an order of magnitude through
avidity effects (Fig. 1B, Table 1). The equilibrium binding constant
(KD) of HGF to c-MET has been measured to be in the picomolar
range [36,37].
A main advantage of the eNK1 monomer over wild-type NK1 is
its increase in thermal stability [29]. We used CD spectroscopy to
determine if structural elements or thermal stability were affected
by creating the dimeric version of the protein. The CD spectra of
the eNK1 monomer and eNK1 dimer were comparable (Fig. 1C),
indicating that covalent dimerization does not perturb secondary
structure. The apparent thermal melting temperature (Tm,eff) of
both proteins was similar: 65.0 ± 0.2 C and 61.9 ± 0.7 C for the
eNK1 monomer and eNK1 dimer, respectively (Fig. 1D, Table 1),
indicating that the dimer maintains the enhanced thermal stability
of its monovalent counterpart compared to wild-type NK1
(Tm,eff = 50.7 ± 0.2 C) [29].
3.2. eNK1 dimer potently activates the c-MET receptor and
downstream signaling pathways
An ideal c-MET agonist is one that would have comparable bio-
logical potency to HGF. We measured the ability of the eNK1 dimer
to activate the c-MET receptor and downstream cell signaling path-
ways in HUVECs compared to the eNK1 monomer and HGF (Fig. 2).
Phosphorylation of c-MET and downstream targets Erk and Akt
lead to cellular responses of survival, migration, and proliferation
[2]. The eNK1 monomer was unable to activate c-MET, Erk, or
Akt to an appreciable degree, although weak activation levels were
seen at longer exposure times. In contrast, the eNK1 dimer stimu-
lated phosphorylation of c-MET, Erk, and Akt with similar potency
to full-length HGF at concentrations of 1 nM (Fig. 2A) and 10 pM
(Fig. 2B). Similar results were obtained in the human lung carci-
noma cell line A549 (Supplementary Fig. 1). HGF and the eNK1
dimer also activated c-MET phosphorylation to equivalent levels
using the DiscoveRx PathHunter system (Fig. 2C). In this assay,
Fig. 2. Phosphorylation of c-MET and downstream targets. HGF, eNK1 monomer, or eNK1 dimer was added to HUVEC cells at concentrations of (A) 1 nM, or (B) 10 pM for the
indicated timepoints. Negative control indicates basal media alone without added c-MET agonist. Western blots of cell lysates analyzed using a phospho-speciﬁc antibody
(‘p’) indicate activated c-MET, Akt and Erk. Total protein levels of c-MET, Akt and Erk are shown to relate the fraction of phosphorylated protein to total protein between
treatment conditions. Tubulin is shown as a control to indicate total protein loaded per gel lane prior to Western blotting. (C) HGF, eNK1 monomer, or eNK1 dimer were added
to c-MET expressing cells, and activation was quantiﬁed using the DiscoveRx PathHunter system, which measures chemiluminescence as a readout. HGF is depicted as ﬁlled
squares, eNK1 monomer as ﬁlled circles and eNK1 dimer by open circles.
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more than an order of magnitude higher compared to the eNK1
dimer and HGF, and exhibited a lower maximal level of c-MET
phosphorylation.
3.3. eNK1 dimer stimulates increased cell migration compared to eNK1
monomer
Tissue regeneration requires a host of biological processes
including cell migration into the wound area and cell proliferation
[38]. A directional migration assay was used to investigate cell
migration in response to HGF, eNK1 dimer, or eNK1 monomer. In
this assay, a scratch is created in a monolayer of HUVECs as an
in vitro proxy for wound healing, and cell migration into this void
is measured over time. Preliminary experiments showed only mar-
ginal increases in cell migration upon the addition of any of theFig. 3. Cell migration assay. Top images show representative HUVEC wounds 24 h follow
graph shows the fraction of wound closure with increasing concentrations of HGF or NK
control represents incubation of cells in complete growth media. Signiﬁcance was me
P < 0.005 for all corresponding concentrations between HGF/eNK1 dimer and eNK1 monthree ligands alone. However, enhanced cell migration was
observed when HGF was combined with FGFb (Supplementary
Fig. 2), a growth factor whose receptor is known to crosstalk with
c-MET [39,40]. HGF or the eNK1 dimer, when combined with
10 pM FGFb, showed signiﬁcant dose-dependent increases in cell
migration into the wound area over 24 h compared to the FGFb-
only negative control, with the eNK1 dimer showing levels of activ-
ity approaching that of HGF (Fig. 3). In contrast, the eNK1 mono-
mer stimulated minimal amounts of cell migration only at the
highest concentration tested.
3.4. eNK1 dimer stimulates increased cell proliferation compared to
eNK1 monomer
Finally, we tested the ability of the eNK1 dimer to stimulate
HUVEC proliferation compared to the eNK1 monomer and HGF.ing incubation with 10 pM FGFb and 1 nM HGF, eNK1 monomer, or eNK1 dimer. Bar
1 variant. Negative control represents media containing 10 pM FGFb alone. Positive
asured against the negative control except where indicated. ⁄P < 0.05, ⁄⁄P < 0.005.
omer.
Fig. 4. Cell proliferation assay. HUVECs were incubated with varying concentra-
tions of HGF, eNK1 monomer, or eNK1 dimer with 10 pM FGFb for 24 h. Cell
proliferation was measured by uptake of tritiated thymidine into newly synthesized
DNA. Signiﬁcance was measured against the negative control (FGFb only) unless
otherwise indicated. ⁄P < 0.05, ⁄⁄P < 0.005.
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midine into newly synthesized DNA (Fig. 4). For this assay, the
addition of 10 pM FGFb was again required to amplify the biolog-
ical effects of ligand stimulation. Both HGF and the eNK1 dimer
showed positive dose response curves, with the eNK1 dimer stim-
ulating slightly lower levels of cell proliferation. In contrast, the
eNK1 monomer stimulated proliferation appreciably over back-
ground levels only at the highest concentration tested.
4. Discussion
c-MET activators are currently under clinical development for a
variety of biomedical applications. In particular, recombinant HGF
is undergoing testing in human clinical trials for treatment of
spinal cord injury (Phase I/II trial), amyotrophic lateral sclerosis
(Phase I trial) [41,42], hepatitis (Phase I/II trial) [43], and venous
leg ulcers (Phase I/II trial) [44]. In parallel with these efforts, chal-
lenges with recombinant expression and poor stability of HGF have
motivated gene therapy approaches for protein production, which
are being evaluated in clinical trials for peripheral arterial disease
[45], critical limb ischemia [46], and amyotrophic lateral sclerosis
[47]. In addition, a small molecule HGF mimetic is in Phase II trials
for myocardial infarction [48]. Work from academic research
groups has explored the use of HGF fragments as alternative c-
MET agonists [5,19–22]; however, these proteins possess similar
limitations as HGF.
Development of NK1-based c-MET effectors have been
informed by insights into the HGF/NK1 mechanism of action
[11,21,26,30,49,50]. NK1 is the minimal fragment of HGF that has
been shown to activate c-MET; however, it functions as a weak
agonist [23]. Compared to wild-type NK1, the engineered NK1 var-
iant identiﬁed in our previous work (eNK1; also termed M2.2
D127N) has identical functional activity, a 15 C increase in ther-
mal stability, and up to 40-fold increased recombinant expres-
sion yield from yeast cultures, but is still limited by low
biological potency compared to HGF. In the present study we
showed that a covalently-crosslinked dimer created from eNK1
retains this high stability and binds to c-MET with a relativeafﬁnity that is over an order of magnitude stronger than the
eNK1 monomer due to avidity effects. Because of the tight afﬁnity
of this eNK1 dimer, avoiding ligand depletion conditions that affect
Langmuir binding isotherms would have required reaction vol-
umes of over 1 liter and several days to reach equilibrium, which
is not compatible with cell surface binding assays. Thus, our bind-
ing measurements may underestimate c-MET afﬁnity, but the
picomolar IC50 values we observed for the eNK1 dimer on two dif-
ferent cell lines lie within a similar range of afﬁnities previously
measured for HGF [36,37].
In addition to stimulating c-MET phosphorylation, the eNK1
dimer activated similar cell signaling pathways as HGF, including
downstream targets Akt and Erk, with comparable potency and
temporal effects. The eNK1 monomer induced cell signaling only
at high concentration, highlighting the importance of ligand-med-
iated receptor dimerization for activation. The DiscoveRx PathHun-
ter assay offers a more quantitative measure of c-MET activation,
and the results roughly mirror the Western blot phosphorylation
experiments where the eNK1 dimer activates c-MET to a similar
degree compared to HGF, while the eNK1 monomer activates a
lower level of c-MET phosphorylation at the highest concentration
tested. In functional assays, both the eNK1 dimer and HGF stimu-
lated HUVEC migration and proliferation at low nanomolar con-
centrations, but required the addition of FGFb. In these
experiments, we observed trends of dose response-mediated activ-
ity from protein ligands alone, but these results were not statisti-
cally signiﬁcant. The dependence of c-MET mediated cell
migration and proliferation on FGFb suggests that synergistic
effects of signaling through multiple receptors is necessary for
these biological outputs.
HGF is a unique growth factor, encompassing 6 domains includ-
ing an N-terminal domain, four Kringle domains (K1, K2, K3, and
K4), and a serine protease homology (SPH) domain [1]. While the
NK1 and the SPH domains have been shown to bind both c-MET
and heparin [25,51], the role of the other Kringle domains is
unclear due to the lack of high resolution structural information
available for HGF and c-MET. One likely hypothesis is that the
K2-K4 domains serve to orient HGF in a way that facilitates an
optimal NK1 conformation for dimerization and receptor activa-
tion [49,50]. In our study, dimerization of eNK1 through a covalent
disulﬁde bond obviates the need for these additional HGF domains,
at least for the biological functions tested here, positioning the c-
MET receptor in a conformation that drives activation and cell
signaling.
Comparable agonistic activity observed with the eNK1 dimer
suggests that it could be a suitable alternative to HGF, with the
additional beneﬁts of increased stability and ability to be produced
in a microbial expression system. Future directions of this work
include testing the therapeutic efﬁcacy of the eNK1 dimer in ani-
mal models of disease such as ischemia, multiple sclerosis, and dia-
betes [52–54]. As the eNK1 dimer retains binding to heparin [29], it
may also ﬁnd utility in combination with naturally-derived or syn-
thetic biomaterial scaffolds that contain heparin or heparin-bind-
ing epitopes [55–57] for in vivo applications that require
localized or sustained delivery.
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